argenx NV ADR (ARGX)vsAvalo Therapeutics Inc (AVTX)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
AVTX
Avalo Therapeutics Inc
$13.45
-0.37%
HEALTHCARE · Cap: $248.44M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 2206394% more annual revenue ($4.24B vs $192,000). ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
AVTX
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Intrinsic value data unavailable for AVTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -1.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : AVTX
The strongest argument for AVTX centers on Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : AVTX
The primary concerns for AVTX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while AVTX is a value play — different risk/reward profiles.
AVTX carries more volatility with a beta of 0.89 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 24/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Avalo Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Avalo Therapeutics Inc is a pioneering clinical-stage biotechnology company focused on developing innovative therapies for rare and underserved conditions, particularly in the realm of immunological regulation. With a robust pipeline of proprietary candidates targeting serious diseases with significant unmet medical needs, Avalo leverages its deep expertise in disease mechanisms to advance its therapeutic programs through rigorous clinical trials. The company's dedication to scientific innovation and a patient-centric approach positions it to navigate the complexities of the biopharmaceutical industry effectively, with the goal of delivering transformative therapies to improve patient outcomes.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?